PT  - JOURNAL ARTICLE
AU  - Fusaroli, Michele
AU  - Polizzi, Stefano
AU  - Menestrina, Luca
AU  - Giunchi, Valentina
AU  - Pellegrini, Luca
AU  - Raschi, Emanuel
AU  - Weintraub, Daniel
AU  - Recanatini, Maurizio
AU  - Castellani, Gastone
AU  - Ponti, Fabrizio De
AU  - Poluzzi, Elisabetta
TI  - Unveiling the Hidden Toll of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
AID  - 10.1101/2023.11.17.23298635
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.17.23298635
4099  - http://medrxiv.org/content/early/2023/11/17/2023.11.17.23298635.short
4100  - http://medrxiv.org/content/early/2023/11/17/2023.11.17.23298635.full
AB  - Introduction Adverse drug reactions significantly impact patients’ lives, yet their influence is often underestimated in treatment decisions and monitoring. Impulsivity induced by dopaminergic agents can lead to impaired social functioning and quality of life.Aim This study assesses impulsivity burdens from pramipexole and aripiprazole, pinpointing key symptoms for targeted mitigation.Method Leveraging data from the FDA Adverse Event Reporting System (January 2004 - March 2022), we employed the Information Component to identify the syndrome of signs and symptoms disproportionately co-reported with drug-induced impulsivity. Using composite network analyses (PPMI, Ising, ϕ) we characterized clusters of co-reported events (i.e., subsyndromes). Finally, we assessed the secondary impact of drug-induced impulsivity modeling our dataset as a chain of directed connections (Bayesian network).Results The drug-induced impulsivity syndrome (respectively 56 and 107 events in pramipexole and aripiprazole recipients), primarily encompassed psychiatric, social, and metabolic events, segregated into subsyndromes such as delusional jealousy and dopamine dysregulation syndromes among pramipexole recipients, and obesity-hypoventilation syndrome and social issues among aripiprazole recipients. Anxiety and economic problems emerged as pivotal nodes in the exacerbation of the syndromes.Conclusion Drug-induced impulsivity places a substantial burden on patients and their families, with manifestations shaped by the underlying disease. Network approaches, exploring intricate symptom connections and identifying pivotal symptoms, complement traditional techniques and clinical judgment, providing a foundation for informed prescription and targeted interventions to alleviate the burden of adverse drug reactions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.htmlI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data we used comes from the FDA Adverse Event Reporting System (FAERS), and is made publicly available by the FDA as quarterly data downloadable at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html. The algorithm for cleaning FAERS data is open-source at https://github.com/fusarolimichele/DiAna, and the cleaned database is available on an OSF repository and through the R package DiAna. https://osf.io/k9v6s/